InnovAge Lifts Long-Term Targets: FY2027 Revenue Guidance of $1.05B-$1.085B and Adjusted EBITDA of $105M-$115M
TREE NEWS reports: InnovAge Holding Corp. (NASDAQ: INNV), a provider of Program of All-Inclusive Care for the Elderly (PACE) services, issued its first formal multi-year financial outlook on Tuesday, projecting fiscal 2027 revenue of $1.05 billion to $1.085 billion and adjusted EBITDA of $105 million to $115 million. The company also said it expects to grow its participant census by 5% to 7.5% annually over that period, signaling confidence in its operational turnaround and expansion strategy.
What the Guidance Implies
The FY2027 targets represent a significant step up from current levels. For fiscal 2025, analysts expect revenue of roughly $850 million and adjusted EBITDA near $75 million. The implied compound annual growth rate of about 11% in revenue and 15% in adjusted EBITDA over two years suggests management sees durable tailwinds from its PACE model, which provides integrated medical and social services to frail seniors, allowing them to remain in their homes rather than move to nursing facilities.
InnovAge’s census growth guidance of 5%-7.5% annually is particularly notable. The company has been working to rebuild its census after regulatory suspensions in California and Colorado in 2021-2022, which led to enrollment freezes. Since then, it has reopened intake at several centers and expanded into new markets. Achieving sustained mid-single-digit census growth would demonstrate that the operational fixes are taking hold and that the value proposition of PACE is resonating with referral partners and families.
Market Impact Analysis
Stocks: InnovAge shares have been volatile, trading near $10-$12 range recently as investors weighed recovery progress against regulatory overhang. The new guidance could provide a clearer baseline, potentially reducing uncertainty. If the market views the targets as credible, the stock may re-rate higher, but skepticism about census growth timing could cap upside. Peer PACE operators and broader senior-care stocks may also see sympathy moves, though InnovAge is the purest play.
Bonds: InnovAge has minimal debt, so the direct impact on credit markets is negligible. However, the guidance could improve sentiment for healthcare services issuers with similar exposure to government-funded programs, as it signals stable reimbursement under Medicare and Medicaid.
Crypto and Commodities: No direct impact. This is a company-specific story with no macro or sector-wide commodity implications.
Currencies: No direct impact. InnovAge operates solely in the U.S., and its financials are dollar-denominated.
Why It Matters for Investors
InnovAge’s outlook is a litmus test for the PACE industry’s post-pandemic recovery. The company was one of the fastest-growing PACE providers before regulatory issues hit, and its ability to re-accelerate census growth is a key indicator of whether the model can scale profitably. For healthcare investors, the guidance also offers insight into how government-funded senior care providers are positioning for an aging U.S. population, a secular trend that is likely to accelerate demand for cost-effective alternatives to institutional care.
Moreover, the adjusted EBITDA margin implied by the guidance (roughly 10%) is modest but improving, suggesting operating leverage will kick in as centers reach scale. If InnovAge can execute, it could become a consolidator in the fragmented PACE space, creating long-term shareholder value. However, execution risk remains: census growth depends on regulatory approvals, referral relationships, and the company’s ability to staff centers in a tight labor market.
Key Takeaways for Investors
- First formal guidance: InnovAge provided FY2027 revenue and adjusted EBITDA targets, a new level of transparency for the company.
- Growth driver: 5%-7.5% annual census growth is the key assumption; sustained execution would validate the turnaround.
- Margin expansion: Adjusted EBITDA growth outpaces revenue, implying operating leverage.
- Risk factors: Regulatory overhang, labor costs, and reimbursement rate changes are the main threats to the outlook.
- Action: Investors should monitor quarterly census numbers and any state-level regulatory actions to gauge progress against the targets.
